SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market weighs potential near-term rate cuts against longer-term economic concerns and Japan bond yield surge. Community members are actively discussing whether the recent AI-driven rally is sustainable, pointing to specific levels and potential downside risks, while some are anticipating a year-end rally.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amid discussions about its AI strategy, particularly the AWS re:Invent conference and new AI chip developments that are intended to compete with Nvidia. The community is weighing the potential impact of these innovations on Amazon's market position and profitability, along with its ongoing partnerships. Some are concerned over high spending and performance, while others express optimism about long-term cloud and AI growth.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

PLRZ is trending due to positive preclinical data for its intranasal naloxone hydrogel, with the community actively debating whether the stock will continue to squeeze or face dilution. The stock's low float and previous reverse splits are fueling volatility, while some traders are drawing comparisons to similar plays like $SMX and anticipating a potential multi-day run.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending amid discussions about its recent earnings beat and future prospects in the AI automation space; the community is weighing in on whether the company can sustain growth and capitalize on its partnerships with major tech players. Some traders are highlighting the high short interest and potential for a squeeze, while others focus on long-term potential and the stock's undervaluation relative to its peers. Discussions also include the upcoming fireside chat at the Barclays Global Technology Conference.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community discusses potential bullish formations, historical transactional advantages, and potential for a spot ETF. Some speculate on an upcoming golden cross and a breakout against Bitcoin, while others express frustration with its historical performance. Discussions also highlight Litecoin's reliability for payments and potential role in the digital silver narrative.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as community members discuss its AI initiatives, particularly the Gemini model and TPU technology, and speculate on potential partnerships. Some traders are noting technical indicators and option activity, while others assess its competitive positioning against key players like NVDA. The stock's potential to reach a $4 trillion market cap is also being debated.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

BRK.B is trending amid discussion of its massive cash reserves and strong Q3 earnings, with operating profits surging. Community chatter revolves around Berkshire's strategy given the current market conditions, particularly regarding potential acquisitions or share buybacks. Some investors view BRK.B as a safe haven during market uncertainty, while others question its valuation and future performance post-Buffett.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to positive Phase 3 data for their DMD treatment, sparking buyout speculation and a potential short squeeze. The community is buzzing about the implications for FDA approval and the possibility of partnerships with larger pharmaceutical companies. However, some traders express skepticism, citing past FDA setbacks and statistical significance concerns.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 2x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending as traders weigh market volatility amid economic data and global events. Community members are actively discussing potential market corrections, hedging strategies, and the impact of quantitative tightening. The upcoming reverse split is also a key point of discussion, with some traders expressing concerns about its impact on options.

Moonriver is a fully Ethereum-compatible smart contract parachain on Kusama. Due to this Ethereum-like design and developer-friendly approach, Moonriver has attracted dozens of projects to build on it: https://moonbeam.network/community/projects/. It does this by providing a full EVM implementation, a Web3-compatible API, and bridges that connect Moonriver to existing Ethereum networks. This allows developers to deploy existing Solidity/Vyper smart contracts and DApp frontends to Moonriver with minimal changes.  It is intended to be a companion network to Moonbeam (on Polkadot), where it will provide a permanently incentivized canary network. New code will ship to Moonriver first, where it can be tested and verified under real economic conditions. Once proven, the same code will ship to Moonbeam on Polkadot.

Moonriver

Moonriver is trending as community members discuss its potential for significant gains, drawing comparisons to past surges and highlighting its low supply. Some are speculating on future listings and its relationship to the Polkadot ecosystem. Technical analysis and staking opportunities are also being actively discussed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fossil Group (FOSL) shares were down nearly 39% in premarket trading on Thursday morning after the company said on Thursday that it has further extended the&nbsp;expiration of the exchange offer concerning its 7.00% Senior Notes due 2026.The company also noted that it has extended the consent solicitation and its concurrent rights offering from October 15 to October 22.Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.Retail sentiment on Fossil Group jumped to ‘extremely bullish’ from ‘bearish’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.On Wednesday, Fossil Group’s shares had closed up 41.5% at a two-and-a-half-year high of $3.75 following the news of the IPO of its Indian unit. According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-15/fossil-india-is-said-to-weigh-ipo-that-could-raise-400-million">Bloomberg News report</a>, Fossil India was in talks to raise $300 million to $400 million by selling as much as a 25% stake.The report noted that the talks were ongoing and that the size of the IPO or the possible timing of the offering could change.&nbsp;In early 2025, as part of a plan to save costs, the company planned to shut down around 50 retail locations and shift certain international markets to a distributor model. The firm is home to several premium brands such as Fossil Watches and Michele.&nbsp;<a href="https://stocktwits.com/symbol/VERI">Shares of Fossil Group</a> have jumped 125% this year and gained nearly 213% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>

Sign of Fossil Group outside a store in Orlando, Florida.

FOSL Stock Plunges After Extending Exchange Offer For Its Senior Notes Due 2026

Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.

Equity

Shares of Ovid Therapeutics Inc. (OVID) jumped 18% in the pre-market session on Friday after the company announced positive results from an early-stage trial of its OV329, as well as the pricing of a $175 million placement.OV329 is being developed for the potential treatment of rare and treatment-resistant forms of epilepsy and seizures. It is believed to work by reducing the activity of GABA-AT, an enzyme that degrades GABA, an important inhibitory neurotransmitter in the brain. An increase in levels of GABA in the brain can potentially suppress neuronal hyperexcitability, known to cause seizures, the company said.The early-stage <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-announces-positive-topline-results-for-the-next-generation-GABA-aminotransferase-inhibitor-OV329-that-demonstrate-strong-inhibitory-activity-and-a-potential-best-in-category-safety-profile/default.aspx">study</a>, which enrolled 68 healthy volunteers, was aimed at evaluating the safety, tolerability, pharmacokinetic, and pharmacodynamic activity of OV329. The drug demonstrated statistically significant inhibition of GABA-AT, matching or exceeding the inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor Vigabatrin (VGB), the company said. The drug also demonstrated a favorable safety and tolerability profile, it added. &nbsp;The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures. The study is expected to start in Q2 2026 and be completed in mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OVID">OVID stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_8_04_20_AM_png_cfbcdadc7f.webp" alt="OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>Separately, Ovid on Friday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-Therapeutics-Announces-Pricing-of-Private-Placement-Totaling-up-to-175-Million-in-Gross-Proceeds/default.aspx">announced</a> the pricing of a private placement totaling up to $175 million in proceeds. The financing transaction included participation from new investors alongside existing ones, the company said.The company stated that it intends to utilize the net proceeds from the initial closing of the financing deal, in conjunction with its existing cash, cash equivalents, and marketable securities, to fund research and development, general corporate expenses, and working capital requirements. It added that it expects its cash to fund its operating plan into 2028.A Stocktwits user applauded the funding news as “huge.”<stembedurl>https://stocktwits.com/Skeetz99/message/630905995</stembedurl>OVID stock is up 76% this year and approximately 45% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/esperion-shares-rally-after-patent-litigation-settlement-for-cholestrol-drugs/chCujWhR3Qb">Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why

The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures.

Eastman Kodak Co. (KODK) experienced a 366% surge in Stocktwits retail chatter in the last 24 hours after the photographic film products maker announced on the X platform that it is making a major move to strengthen pharmaceutical manufacturing within the U.S.&nbsp;&nbsp;<figure class="image"><img style="aspect-ratio:587/183;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_24_082242_png_3c927c29c7.webp" alt="Screenshot 2025-07-24 082242.png" width="587" height="183"></figure>A Stocktwits user said it is the ‘Kodak Moment’ for the company.<stembedurl>https://stocktwits.com/ScottBrownMBA/message/622209783</stembedurl>Another user expressed optimism, linking the news to the U.S. Japan trade deal.<stembedurl>https://stocktwits.com/Zorrelak/message/622217804</stembedurl>However, retail sentiment around the stock remained in ‘bearish’ territory with ‘low’ message volume levels.<figure class="image"><img style="aspect-ratio:975/117;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_24_083017_png_ac1c90c79d.webp" alt="KODK’s Sentiment Meter and Message Volume as of 08.30 a.m. ET on July 24, 2025 | Source: Stocktwits" width="975" height="117"><figcaption>KODK’s Sentiment Meter and Message Volume as of 08.30 a.m. ET on July 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/KODK">Eastman Kodak stock</a> inched 0.5% higher in Thursday’s premarket.Kodak ventured into pharmaceuticals after the company was awarded a $765 million federal loan in 2020, aimed at producing pharmaceutical ingredients, as part of a broader effort during the pandemic to strengthen the nation’s medical supply chain.In May of this year, CEO Jim Continenza stated that the company is retrofitting a facility at Eastman Business Park and has committed $20 million to expand U.S. manufacturing, according to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://rbj.net/2025/05/09/kodak-invests-20m-in-rochester-pharma-manufacturing-expansion/?utm_source=chatgpt.com">report</a> from the&nbsp;Rochester Business Journal.&nbsp;In the first quarter (Q1), the company’s revenue declined 1% year-on-year (YoY) to $243 million.&nbsp;“The group’s new cGMP manufacturing facility, which we expect to be online later this year, will expand our current pharma business into manufacturing FDA-regulated diagnostic test reagents. Our investment in the new pharma facility is just one example of our commitment to investing in U.S.-based manufacturing,” said&nbsp;Continenza after the Q1 earnings.As it evolves into pharmaceuticals, Kodak continues to support its traditional film operations and printing systems, including high-speed inkjet technology.Eastman Kodak stock has gained over 8% year-to-date and over 25% in the last 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alphabet-manhattan-associates-at-and-t-draw-heavy-retail-chatter-on-stocktwits/ch8yupaR5HI">Alphabet, Manhattan Associates, AT&amp;T Draw Heavy Retail Chatter On Stocktwits Among Tech Stocks: More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

A Kodak ‘Moment’? Company’s Pharma Expansion Plans Ignite 366% Surge In Retail Chatter

Kodak ventured into pharmaceuticals after the company was awarded a $765 million federal loan in 2020, aimed at producing pharmaceutical ingredients, as part of a broader effort during the pandemic to strengthen the nation’s medical supply chain.

Diversified Energy (DEC) stock gained in pre-market trade on Monday after the company said it would buy Maverick Natural Resources from private equity firm EIG for $1.28 billion.The deal, expected to close in the first half of 2025, would increase the share of oil in Diversified Energy’s total energy production mix.The energy firm said the deal would help nearly double its revenue, and the combined company would have a total production of about 200,000 barrels of oil equivalent per day.The overwhelming majority of Maverick’s production comes from the Western Anadarko Basin, the Ark-La-Tex region of East Texas, and the largest U.S. shale oilfield Permian Basin.Over the past one and half years, the Permian has been a focal point of deal activity in the U.S. due to its robust infrastructure and relatively lower production costs.<a href="https://stocktwits.com/symbol/DEC">Diversified Energy</a> said EIG would own 20% of the combined company once the transaction closes.Rusty Hutson, the CEO of Diversified Energy, will continue to serve in his position after the deal is completed.“The acquired producing assets have demonstrated leading well performance and are a natural fit with our operating advantage and existing acreage,” Hutson said.The company said it is liable to pay $50 million in termination fees under certain circumstances.Retail sentiment on Stocktwits jumped to ‘extremely bullish’ (96/100) territory from ‘bearish’(36/100) a day ago, while retail chatter remained ‘extremely high’.<figure class="image"><img style="aspect-ratio:886/206;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DEC_Jan_27_e4c793b801.JPG" alt="DEC’s Sentiment Meter and Message Volume as of 08:20 a.m. ET on Jan. 27, 2025 | Source: Stocktwits" width="886" height="206"><figcaption>DEC’s Sentiment Meter and Message Volume as of 08:20 a.m. ET on Jan. 27, 2025 | Source: Stocktwits</figcaption></figure>Earlier this month, Diversified Energy had agreed to buy some natural gas assets from Summit Natural Resources for $45 million.Over the past year, the stock has gained 32.5%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/super-micro-stock-crashes-below-30-support-premarket/chbkvyQRov">Super Micro Stock Crashes Below $30 Support Premarket As DeepSeek Fears Rattle AI Stocks: Retail Sentiment Mixed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An oil pumpjack in a field on March 24, 2024 in Grandfalls, Texas. (Photo by Brandon Bell/Getty Images)

Diversified Energy Stock Rises After Deal To Buy Maverick Natural Resources for $1.28B: Retail’s Elated

The deal, expected to close in the first half of 2025, would increase the share of oil in Diversified Energy’s total energy production mix.

Current Price	$23.82
Prev Close	$23.39
Open	$23.50
Dividend Yield	N/A
50-Day Moving Average	$22.58
Beta	N/A
Avg. Volume	179,215.05
PE Ratio	N/A

52-Week High	$23.83
52-Week Low	$16.55
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

BSVO
EA Series Trust - EA Bridgeway Omni Small-Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BSVO News

BSVOEA Series Trust - EA Bridgeway Omni Small-Cap Value ETF